Life Sciences Summit 2016: November 2-3, NYC

The Life Sciences Summit is an early stage investor and business development conference that highlights innovation. On November 2-3, 2016, emerging biotech companies and academic innovators will convene in New York City to connect with investors and strategic partners with the goal of moving new discoveries through clinical development. The two-day program features corporate presentations by promising young companies with transformative science that targets unmet medical needs. It also features informative plenary sessions, business workshops, and therapeutic sessions.

There is still time to register and participate in this innovative conference that provides attendee the opportunity to networking with potential investors and strategic partners. REGISTER TODAY!

 

Posted in Uncategorized

iCell Gene Therapeutics Granted Orphan Drug Designation

iCell Gene Therapeutics, a CFB client company, has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its chimeric antigen receptor engineered T-cells directed against the target protein CD4 (CD4CAR) for the treatment of peripheral T-cell lymphoma (PTCL). The Orphan Drug Designation program provides orphan status, and associated development incentives, to drugs and biologics intended for the safe and effective treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the U.S. Read more about the designation and company here.

iCell

Posted in Uncategorized

Codagenix Receives Phase I SBIR Grant for Swine Influenza Virus Vaccine

Codagenix, a CFB client company, has announced that it has been awarded a $99,710 Phase I Small Business Innovation Research (SBIR) grant from the United States Department of Agriculture (USDA) to commence the development of an influenza vaccine for swine. Codagenix will apply its next-generation platform technology to construct a vaccine against influenza viruses that infect swine, which, according to the USDA’s 2014 Census of Agriculture is a $22.5 billion industry here in the United States. Read more here.

logo

BIO 2016

bio2016c

The Center for Biotechnology team recently ventured out to San Francisco for BIO’s annual International Convention. Through the support of Empire State Development and the Long Island Bioscience Hub, the Center for Biotechnology was able to support six Long Island emerging biotech companies to attend the meeting: Alpha-1 Biologics Corporation, Codagenix, Inc., DepYMed, Inc., iCell Gene Therapeutics, PhD Skin Care LLC and Vela Therapeutics. These companies were joined in the New York Pavilion by more than two dozen other companies and entities representing New York State.

Long Island and New York City regional companies Alpha-1 Biologics, Vela Therapeutics, Intrommune Therapeutics, PainQX, Serendipity Biotech, ENB Therapeutics, and QuickSilver Biosystems all were recipients of grants from Empire State Development and NewYorkBio which also assisted their participation in the event. These companies were tapped to present in the New York Pavilion along with six other companies from upstate New York.

Envisagenics, ENB Therapeutics, PainQx, QuickSilver and Abcombi BioSciences, all New York State Companies, were invited to participate in the BIO 2016 “Start-Up Stadium” which provide start-up companies with the opportunity to pitch to key members of the investment community, venture philanthropy groups, and BIO attendees. The participating investors provided live feedback and judged the sessions.

In addition, six Long Island Bioscience Hub faculty members were invited to participate in the meeting for the first time. These NIH-REACH program supported faculty attended with the goal to learn more about the commercialization process, how it applies to their translational research, and to engage in the partnering process and meet with potential strategic contacts. Center staff met with over 40 strategic partners over the course of the meeting and follow up is underway.

bio2016b

SBIR/STTR Grant Proposal Writing Clinic

SBIR/STTR Grant Proposal Writing Clinic
July 13th and 14th, 8:30am – 4:30am
Small Business Development Center
Stony Brook University R&D Park

The Small Business Development Center (SBDC) at Stony Brook University is holding a free SBIR/STTR Phase I Proposal Writing Clinic July 13, 2016, followed by one-on-one counseling for in process SBIR/STTR proposals on July 14, 2016. Presented and instructed by Sharon Ballard of Enable Ventures, Inc. This clinic will hone your skills and help you to prepare proposals for Phase I or Phase II SBIR/STTR grants.

In order to participate in the clinic you must become a SBDC client. The SBDC will examine your proposed idea to make sure it will qualify for this program. Space in the July clinic is limited. The deadline for submission is June 17, 2016.

In order to start the process please click on the link below to get the proposal application questionnaire:
https://drive.google.com/file/d/0B3Z_tmGrNoJ0Z01XSElZRFNLS3M/view?usp=sharing

Please answer the questions and submit those answers via soft copy to the following email address: sbdc@stonybrook.edu. The submissions will be reviewed by committee. Those selected to participate will be notified after June 17th.

To register or for more information call 631-632-9837 or email sbdc@stonybrook.edu

New York-color with band_400 SBDC

SBU-vert_2clr_rgb_72ppi